PARADISE consortium attended to a new Plenary Meeting in person this time the 28th and 29th of April 2025. We were lucky to meet all of us in in the University of Freiburg, Germany on the invitation of Moritz team.
Over two days in the city of Freiburg, the consortium made significant progress in discussions about patient data, samples, and biomarkers that will be used to develop a predictive tool through complex statistical models. As the PARADISE predictive tool is powered by AI, a primary focus of the meeting was ensuring that both the tool and its underlying science are transparent and explainable. This is crucial for gaining the trust of clinicians who may use it and patients who could benefit from it. To support these discussions, we had the opportunity to gather several guest experts who spoke about the latest developments regarding the AI Act and its practical implementation. Additionally, three vasculitis patients were present to provide valuable insights from the patient perspective.
